Post COVID-19 AA amyloidosis of the kidneys with rapidly progressive renal failure

References

• WHO. COVID-19 Weekly Epidemiological Update Edition 48. published 2021 Jul 13. 20210709_Weekly_Epi_Update_48_draft.pdf
   Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
   PubMed Web of Science ®Google Scholar
• Mahase E. Coronavirus COVID-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020;368:m641.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care Med. 2020;46:846–848.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Luo R, Wang K. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–838.
   PubMed Web of Science ®Google Scholar
• Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–218. DOI:10.1016/j.kint.2020.05.006
   PubMed Web of Science ®Google Scholar
• Kissling S, Rotman S, Gerber C, et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int. 2020;98:228–231.
   PubMed Web of Science ®Google Scholar
• Larsen C, Bourne T, Wilson J. Collapsing glomerulopathy in a patient with COVID-19. Kidney Int Rep. 2020;5:935–939.
   PubMed Web of Science ®Google Scholar
• Peleg Y, Kudose S, D’Agati V, et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep. 2020;5(6):940–945. DOI:10.1016/j.ekir.2020.04.017
   PubMed Web of Science ®Google Scholar
• Wu H, Larsen C, Hernandez-Arroyo C, et al. AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype. J Am Soc Nephrol. 2020;31:1688–1695.
   PubMed Web of Science ®Google Scholar
• Mir TH. Thrombotic Microangiopathy (aHUS/iTTP) Reported so Far in Covid -19 patients: the virus alone or an omnium gatherum of mechanisms and etiologies? Crit Rev Oncol Hematol. 2021 Apr;162:103347.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361–2371.
   PubMed Web of Science ®Google Scholar
• Merlini G, Saraiva MJ, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Dec;25(4):215–219.
   PubMed Web of Science ®Google Scholar
• Chen M, Wu Y, Jia W, et al. The predictive value of serum amyloid a and C-reactive protein levels for the severity of coronavirus disease 2019. Am J Transl Res. 2020 Aug 15;12(8):4569–4575.
   PubMed Web of Science ®Google Scholar
• Haroun RA, Osman WH, Eessa AM. Interferon-γ induced protein 10 (IP-10) and serum amyloid a (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity. Life Sci. 2021 Mar 15;269:119019. DOI:10.1016/j.lfs.2021.119019.
   PubMed Web of Science ®Google Scholar
• Galkin AP. Hypothesis: aA amyloidosis is a factor causing systemic complications after coronavirus disease. Prion. 2021;15:53.
   PubMed Web of Science ®Google Scholar
• Jana AK, Greenwood AB, Hansmann UHE, et al. The effect of SARS-COV-2 infections on amyloid formation of serum amyloid A. 2021. bioRxiv preprint. DOI:10.1101/2021.05.18.444723
   Google Scholar
• Medrano AS, Méndez JL, Vidal MT, et al. Secondary amyloidosis and rapidly progressing renal insufficiency. A clinico-pathologic study. Med Clin. 1990 Jun 23;95(4):130–132.
   PubMedGoogle Scholar
• Çelebi Z, Kiremitçi S, Sadioğlu R, et al. Rapidly progressive renal failure in AA Amyloidosis: a new clinical and histopathological entity for an old disease. Turkish J Nephrol. 2020;29:289–296.
   Web of Science ®Google Scholar
• Obicia L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012;142:w13580.
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542–554. DOI:10.1016/j.molmed.2022.04.007
   PubMed Web of Science ®Google Scholar
• Sofie Nyström S, Hammarström P. Amyloidogenesis of SARS-CoV-2 Spike Protein. bioRxiv preprint December 17, 2021. DOI:10.1021/jacs.2c03925
   Google Scholar
• Tetz G, Tetz V. Prion-like domains in spike protein of SARS-CoV-2 differ across its variants and enable changes in affinity to ACE2. Microorganisms. 2022;10:280. 1–7.
   Web of Science ®Google Scholar
• Sene S, Kyriakopoulos AK, Nigh G, et al. SARS-CoV-2 spike protein in the pathogenesis of prion-like diseases. Diseases. 2022;10:2–15.
   Google Scholar
• Perez JC, Moret-Chalmin C, Montagnier L. Towards the emergence of a new form of the neurodegenerative Creutzfeldt-Jakob disease: twenty six cases of CJD declared a few days after a COVID-19 “vaccine” Jab. Scienceopen.com. 2022. DOI:10.5231/zenodo.6641999
   Google Scholar